GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SynAct Pharma AB (OSTO:SYNACT) » Definitions » Institutional Ownership

SynAct Pharma AB (OSTO:SYNACT) Institutional Ownership : 3.15% (As of Jun. 15, 2024)


View and export this data going back to 2016. Start your Free Trial

What is SynAct Pharma AB Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, SynAct Pharma AB's institutional ownership is 3.15%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, SynAct Pharma AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, SynAct Pharma AB's Float Percentage Of Total Shares Outstanding is 0.00%.


SynAct Pharma AB Institutional Ownership Historical Data

The historical data trend for SynAct Pharma AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SynAct Pharma AB Institutional Ownership Chart

SynAct Pharma AB Historical Data

The historical data trend for SynAct Pharma AB can be seen below:

2023-07-31 2023-08-31 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 2.19 2.29 3.27 3.34 3.58 3.61 3.59 3.61 3.09 3.15

SynAct Pharma AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


SynAct Pharma AB (OSTO:SYNACT) Business Description

Traded in Other Exchanges
Address
Sheelevagen 2, Lund, SWE, 223 81
SynAct Pharma AB is a clinical-stage biotech company focused on resolving inflammation through selective activation of the melanocortin system. The company has a platform technology based on a new class of drug candidates that target acute exacerbations in chronic inflammatory diseases with the primary aim of stimulating natural healing mechanisms. AP1189, the company's lead drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.

SynAct Pharma AB (OSTO:SYNACT) Headlines

No Headlines